Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07385443

The Spanish National Registry for Myotonic Dystrophy Type 1

Myotonic Dystrophy Type 1 (DM1) is a rare genetic neuromuscular condition that can affect multiple organs and varies widely in how it presents. DM1 is the most common form of adult-onset muscular dystrophy, with an estimated prevalence of approximately 1-5 per 10,000 people. In Spain, the condition shows notable regional differences, making it especially important to understand its characteristics within the population.

The aim of this study is to support a research initiative designed to better characterise DM1. We are developing a comprehensive national registry, collecting patient-reported information, clinical data and omics data that will improve our understanding of the disease and help identify individuals who may be eligible for clinical trials.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The DM1-Hub Patient Registry (https://www.dm1spain.com/) aims to recruit individuals living in Spain with a confirmed genetic diagnosis of myotonic dystrophy type 1 (DM1). Participants may be referred by healthcare professionals or patient organizations. They may also learn about the registry through outreach activities, informational materials, collaborations with national and local patient associations, DM1-Hub events, or through their own online searches.

After completing the informed consent process with their neurologist, participants are connected with the DM1-Hub patient support staff assigned to their hospital. An appointment is scheduled, and all the data collected is entered into the REDCap database.

The objective of this study is to establish a Natural History Patient Registry for individuals with DM1 in Spain. Participants will be invited to take part in follow-up assessments to support the characterization of disease progression over time. A parallel control group will also be recruited to facilitate biomarker discovery and improve understanding of factors associated with disease prognosis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1) through genetic testing.

Exclusion criteria

  • There are no exclusion criteria for the registry

Treatment and study plan

Patient Registry

Other

Patient Registry

Primary outcomes

  1. Genomic Caracterization

    Time frame: 1 year, year 1

    Long-read genomic sequencing analyses encompassing CTG expansion characterization and whole-genome genetic and epigenetic profiling.

Secondary outcomes

  1. Proteomic Characterization

    Time frame: 1 year, year 1

    Biomarker evaluation

  2. WAIS IV neuropsychological tests

    Time frame: 2 years, year 1

    IQ, memory, attention, language

  3. vHOT

    Time frame: 1 year, year 1

    Video Hand Opening Time, clinical measure for Myotonic Dystrophy (DM1) tracking hand reopening speed

  4. Muscular Impairment Rating Scale (MIRS)

    Time frame: 1 year, year 1

    The Muscular Impairment Rating Scale is a 5-point ordinal clinical scale used to evaluate the severity of muscular impairment in patients with myotonic dystrophy.

    Scores range from 1 (minimal or no impairment) to 5 (severe muscle impairment). Higher scores indicate worse functional impairment.

  5. Hand Grip Strength

    Time frame: 1 year, year 1

    Hand grip strength is assessed as a measure of upper limb muscle strength using a hand-held dynamometer. Grip strength is measured separately in the dominant and non-dominant hand, and recorded in kilograms (kg).

    For each hand, three consecutive attempts are performed, alternating between hands to minimize fatigue. The maximum value (best of three attempts) for each hand is recorded and used for analysis.

    Higher values indicate better muscle strength and functional outcome, while lower values reflect greater muscular impairment.

  6. 6MWT

    Time frame: 1 year, year 1

    Six-Minute Walk Test

  7. 10MWRT

    Time frame: 1 year, year 1

    10-meter Walk/Run Test

  8. 30CST

    Time frame: 1 year, year 1

    30-Second Chair Stand Test

  9. FVC

    Time frame: 1 year, year 1

    Forced Vital Capacity (L)

  10. Electrocardiogram (ECG)

    Time frame: 1 year, year 1

    The following ECG-derived parameters and abnormalities are recorded:

    • PR interval duration (milliseconds)
    • QRS complex duration (milliseconds)
    • Presence of atrioventricular block (AV block) (yes/no), and AV block grade when present (first degree, second degree Mobitz I, second degree Mobitz II, third degree)
    • Presence of supraventricular arrhythmias (yes/no)
    • Presence of ventricular arrhythmias (yes/no)
    • Other electrocardiographic abnormalities, recorded as free text when applicable

    All measurements are extracted from the ECG tracing according to standard clinical practice.

    Higher PR or QRS durations and the presence of conduction abnormalities or arrhythmias indicate greater cardiac involvement, while normal values and absence of abnormalities indicate preserved cardiac electrical function.

  11. BMI

    Time frame: 1 year, year 1

    Body Mass Index

  12. OBGYN events

    Time frame: 1 year, year 1

    Collection of gynecological clinical history and relevant reproductive health events for participants who opt to provide this information.

  13. GI symptomatology

    Time frame: 1 year, year 1

    Collection of participant-reported gastrointestinal symptoms and related clinical information.

  14. MBS (Myotonia Behaviour Scale)

    Time frame: 1 year, year 1

    Myotonia severity is assessed using the Myotonia Behaviour Scale (MBS), a clinician-reported ordinal scale that evaluates the functional impact of myotonia-related muscle stiffness on daily activities.

    The scale ranges from 0 to 5, with higher scores indicating greater severity and functional interference due to myotonia:

    0: No muscle stiffness

    • Mild stiffness present but easily ignored
    • Stiffness present and occasionally noticeable but does not interfere with daily activities
    • Stiffness requiring increased concentration to perform certain tasks or activities
    • Stiffness interfering with all tasks and daily activities
    • Severe, disabling stiffness requiring constant movement to avoid complete motor blockage

    Lower scores reflect minimal or absent myotonia, while higher scores reflect greater functional impairment due to myotonia.

  15. Modified Rankin Scale (mRS)

    Time frame: 1 year, year 1

    Global disability is assessed using the Modified Rankin Scale (mRS), a widely used ordinal scale measuring the degree of disability or dependence in daily activities.

    The scale ranges from 0 to 6, with higher scores indicating greater disability or death:

    0: No symptoms

    • No significant disability; able to carry out all usual activities despite symptoms
    • Slight disability; unable to perform all previous activities but able to manage own affairs without assistance
    • Moderate disability; requiring some help but able to walk without assistance
    • Moderately severe disability; unable to walk without assistance and unable to attend to bodily needs without help
    • Severe disability; bedridden, incontinent, and requiring constant nursing care and attention
    • Death
  16. Patient-Reported Outcome: Quality of life

    Time frame: 1 year, year 1

    INQoL (Individualized Neuromuscular Quality of Life Questionnaire)

  17. Patient-Reported Outcome: Fatigue

    Time frame: 1 year, year 1

    FSS (Fatigue Severity Scale )

  18. Patient-Reported Outcome: Dietary Habits

    Time frame: 1 year, year 1

    MEDAS-14 (Mediterranean Diet Adherence Screener)

  19. Patient-Reported Outcome: Sleepiness

    Time frame: 1 year, year 1

    DSS (Daytime Sleepiness Scale)

  20. Patient-Reported Outcome: Apathy

    Time frame: 1 year, year 1

    AES (Apathy Evaluation Scale)

  21. Patient-Reported Outcome: Physical Activity

    Time frame: 1 year, year 1

    IPAQ (International Physical Activity Questionnaire)

  22. Patient-Reported Outcome: Mental Health

    Time frame: 1 year, year 1

    MHI-5 (Mental Health Inventory)

Study contacts

Contact information is provided by the study sponsor or research team.

Alvaro S Larran Mottino, Ph.D.

CONTACT

[email protected]

Gisela Nogales Gadea, Ph.D.

CONTACT

[email protected]

(+34) 93 554 3050

Sponsors and collaborators

Lead sponsor

Fundació Institut Germans Trias i Pujol

Other

Collaborators

  • Biobizkaia Health Research Institute
  • Biogipuzkoa Health Research Institute
  • Complejo Hospitalario Universitario de Albacete
  • Germans Trias i Pujol Hospital
  • Hospital Donostia
  • Hospital Infanta Sofia
  • Hospital Univeritario Ntra. Sra. de la Candelaria
  • Hospital Universitario La Fe
  • Hospital Universitario Marqués de Valdecilla
  • Hospital de Basurto
  • Hospitales Universitarios Virgen del Rocío
  • Instituto de Investigacion Sanitaria INCLIVA

Registry information

Official study title

Creación de un Nodo Integral Para la Distrofia Miotónica Tipo 1 en España: Registro clínico, Mapas genómicos, epigenómicos y proteómicos (DM1-Hub)

Acronym: DM1-Hub

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 4, 2026
Registry last updated
Feb 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.